Difference between revisions of "Stub"
m (→FLAI) |
m |
||
Line 1: | Line 1: | ||
− | Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the [[Ontology]]. | + | Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc [[Ontology]] and for historic interest. |
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
+ | =Regimens composed solely of approved drugs= | ||
==3M== | ==3M== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 130: | Line 131: | ||
*[[Mitoxantrone (Novantrone)]] | *[[Mitoxantrone (Novantrone)]] | ||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Amsacrine & IDAC== | ==Amsacrine & IDAC== | ||
Line 389: | Line 380: | ||
*[[Paclitaxel (Taxol)]] | *[[Paclitaxel (Taxol)]] | ||
*[[Bexarotene (Targretin)]] | *[[Bexarotene (Targretin)]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Carboplatin & Paclitaxel (CP) & Cetuximab== | ==Carboplatin & Paclitaxel (CP) & Cetuximab== | ||
Line 466: | Line 444: | ||
*[[Topotecan (Hycamtin)]] | *[[Topotecan (Hycamtin)]] | ||
− | ==Carboplatin & | + | ==Carboplatin & Topotecan== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
− | + | ====Chemotherapy==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | ====Chemotherapy==== | ||
− | |||
*[[Carboplatin (Paraplatin)]] | *[[Carboplatin (Paraplatin)]] | ||
− | + | *[[Topotecan (Hycamtin)]] | |
− | *[[ | ||
− | == | + | ==CBM== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | CBM: '''<u>C</u>'''apecitabine, '''<u>B</u>'''evacizumab, '''<u>M</u>'''itomycin | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *[[Capecitabine (Xeloda)]] | |
− | + | *[[Mitomycin (Mutamycin)]] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | *[[Capecitabine (Xeloda)]] | ||
− | *[[Mitomycin (Mutamycin)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Bevacizumab (Avastin)]] | *[[Bevacizumab (Avastin)]] | ||
Line 674: | Line 612: | ||
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
− | ==Docetaxel & | + | ==Docetaxel & Gefitinib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Line 682: | Line 620: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] | *[[Docetaxel (Taxotere)]] | ||
− | + | ====Targeted therapy==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | ====Targeted therapy==== | ||
*[[Gefitinib (Iressa)]] | *[[Gefitinib (Iressa)]] | ||
Line 878: | Line 794: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | EP, | + | EP, Tamoxifen, RT: '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), Tamoxifen, '''<u>R</u>'''adiation '''<u>T</u>'''herapy |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
Line 888: | Line 804: | ||
*Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]] | *Concurrent [[External_beam_radiotherapy|thoracic radiation therapy]] | ||
− | ==Erlotinib & | + | ==Erlotinib & Sunitinib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Line 896: | Line 812: | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Erlotinib (Tarceva)]] | *[[Erlotinib (Tarceva)]] | ||
− | *[[ | + | *[[Sunitinib (Sutent)]] |
− | == | + | ==Everolimus & Vinorelbine== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Line 904: | Line 820: | ||
|} | |} | ||
===Regimen=== | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Vinorelbine (Navelbine)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Everolimus (Afinitor)]] |
− | |||
− | == | + | ==E-GEMOX== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | E-GEMOX: '''<u>E</u>'''rlotinib, '''<u>GEM</u>'''citabine, '''<u>OX</u>'''aliplatin | ||
===Regimen=== | ===Regimen=== | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Erlotinib (Tarceva)]] | *[[Erlotinib (Tarceva)]] | ||
− | *[[ | + | ====Chemotherapy==== |
+ | *[[Gemcitabine (Gemzar)]] | ||
+ | *[[Oxaliplatin (Eloxatin)]] | ||
− | == | + | ==FAP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | FAP: '''<u>F</u>'''luorouracil, '''<u>A</u>'''lfa interferon, '''<u>P</u>'''latinol (Cisplatin) | ||
===Regimen=== | ===Regimen=== | ||
− | ==== | + | ====Chemotherapy==== |
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
− | *[[ | + | *[[Cisplatin (Platinol)]] |
+ | ====Immunotherapy==== | ||
+ | *[[Interferon alfa-2b (Intron-A)]] | ||
− | == | + | ==FEC & HP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | FEC & HP: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
+ | *[[Epirubicin (Ellence)]] | ||
+ | *[[Cyclophosphamide (Cytoxan)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Trastuzumab (Herceptin)]] |
+ | *[[Pertuzumab (Perjeta)]] | ||
− | == | + | ==FLA== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | FLA: '''<u>FL</u>'''udarabine & '''<u>A</u>'''ra-C (Cytarabine) | |
===Regimen=== | ===Regimen=== | ||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fludarabine (Fludara)]] |
− | *[[ | + | *[[Cytarabine (Ara-C)]] |
− | == | + | ==FLAG-Ida & GO== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | FLAG-Ida & GO: '''<u>FL</u>'''udarabine, '''<u>A</u>'''ra-C (Cytarabine), '''<u>G</u>'''-CSF (Lenograstim), '''<u>Ida</u>'''rubicin, '''<u>G</u>'''emtuzumab '''<u>O</u>'''zogamicin | |
− | ===Regimen=== | + | ===Regimen {{#subobject:44e85e|Variant=1}}=== |
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 2 to 6 |
− | *[[ | + | *[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 4 hours once per day on days 2 to 6, '''given 4 hours after fludarabine''' |
− | + | *[[Idarubicin (Idamycin)]] 8 mg/m<sup>2</sup> IV once per day on days 4 to 6 | |
− | *[[ | ||
− | == | + | ====Growth factor therapy==== |
− | + | *[[Lenograstim (Granocyte)]] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | *[[ | ||
− | |||
− | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Gemtuzumab ozogamicin (Mylotarg)]] |
− | |||
− | == | + | ==FLAI== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | FLAI: '''<u>FL</u>'''udarabine, '''<u>A</u>'''ra-C (Cytarabine), '''<u>I</u>'''darubicin | |
+ | <br>FIA: '''<u>F</u>'''ludarabine, '''<u>I</u>'''darubicin, '''<u>A</u>'''ra-C (Cytarabine) | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Fludarabine (Fludara)]] | *[[Fludarabine (Fludara)]] | ||
*[[Cytarabine (Ara-C)]] | *[[Cytarabine (Ara-C)]] | ||
+ | *[[Idarubicin (Idamycin)]] | ||
− | == | + | ==FOLF-CB== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | FOLF-CB: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>C</u>'''etuximab, '''<u>B</u>'''evacizumab | |
− | ===Regimen | + | ===Regimen=== |
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
− | + | *[[Folinic acid (Leucovorin)]] | |
− | |||
− | |||
− | |||
− | *[[ | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Cetuximab (Erbitux)]] |
+ | *[[Bevacizumab (Avastin)]] | ||
− | == | + | ==FULV & Trimetrexate== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | FULV & Trimetrexate: 5-'''<u>FU</u>''' & '''<u>L</u>'''euco'''<u>V</u>'''orin (Folinic acid), Trimetrexate | |
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
− | *[[ | + | *[[Folinic acid (Leucovorin)]] |
− | *[[ | + | *[[Trimetrexate (Neutrexin)]] |
− | == | + | ==GVP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | GVP: '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine, '''<u>P</u>'''latinol (Cisplatin) | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Gemcitabine (Gemzar)]] |
− | *[[ | + | *[[Vinorelbine (Navelbine)]] |
− | + | *[[Cisplatin (Platinol)]] | |
− | |||
− | *[[ | ||
− | == | + | ==ICE, ATRA, GO== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | ICE, ATRA: '''<u>I</u>'''darubicin, '''<u>C</u>'''ytarabine, '''<u>E</u>'''toposide, '''<u>A</u>'''ll-'''<u>T</u>'''rans '''<u>R</u>'''etinoic '''<u>A</u>'''cid, '''<u>G</u>'''emtuzumab '''<u>O</u>'''zogamicin | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Idarubicin (Idamycin)]] |
− | *[[ | + | *[[Cytarabine (Ara-C)]] |
− | *[[ | + | *[[Etoposide (Vepesid)]] |
+ | ====Targeted therapy==== | ||
+ | *[[All-trans retinoic acid (ATRA)]] | ||
+ | *[[Gemtuzumab ozogamicin (Mylotarg)]] | ||
− | == | + | ==Ixabepilone & Bevacizumab== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Ixabepilone (Ixempra)]] |
− | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Bevacizumab (Avastin)]] |
− | == | + | ==ME== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | ME: '''<u>M</u>'''itoxantrone & '''<u>E</u>'''toposide | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Mitoxantrone (Novantrone)]] |
− | *[[ | + | *[[Etoposide (Vepesid)]] |
− | |||
− | == | + | ==MEV== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | MEV: '''<u>M</u>'''itomycin, '''<u>E</u>'''toposide, '''<u>V</u>'''indesine | ||
===Regimen=== | ===Regimen=== | ||
− | ==== | + | ====Chemotherapy==== |
− | *[[ | + | *[[Mitomycin (Mutamycin)]] |
− | *[[ | + | *[[Etoposide (Vepesid)]] |
+ | *[[Vindesine (Eldisine)]] | ||
− | == | + | ==MFL== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | MFL: '''<u>M</u>'''ethyl-lomustine (MeCCNU), 5-'''<u>F</u>'''U, '''<u>L</u>'''eucovorin (Folinic acid) | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Semustine (MeCCNU)]] |
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
− | *[[ | + | *[[Folinic acid (Leucovorin)]] |
− | |||
− | |||
− | |||
− | == | + | ==MFT== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | MFL: '''<u>M</u>'''ethotrexate, 5-'''<u>F</u>'''U, '''<u>T</u>'''amoxifen | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Methotrexate (MTX)]] |
− | ==== | + | *[[Fluorouracil (5-FU)]] |
− | *[[ | + | ====Endocrine therapy==== |
+ | *[[Tamoxifen (Nolvadex)]] | ||
− | == | + | ==Mitoxantrone & Hydrocortisone== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Mitoxantrone (Novantrone)]] | *[[Mitoxantrone (Novantrone)]] | ||
− | *[[ | + | ====Endocrine therapy==== |
+ | *[[Hydrocortisone (Cortef)]] | ||
− | == | + | ==MMF== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | MMF: '''<u>M</u>'''ethyl-lomustine (MeCCNU), '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''U | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | *[[Semustine (MeCCNU)]] | ||
*[[Mitomycin (Mutamycin)]] | *[[Mitomycin (Mutamycin)]] | ||
− | *[[ | + | *[[Fluorouracil (5-FU)]] |
− | |||
− | == | + | ==MPP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | MPP: '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>P</u>'''rocarbazine | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Melphalan (Alkeran)]] |
− | *[[ | + | *[[Prednisone (Sterapred)]] |
− | *[[ | + | *[[Procarbazine (Matulane)]] |
− | == | + | ==MTP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | MTP: '''<u>M</u>'''yocet (Non-pegylated liposomal doxorubicin), '''<u>T</u>'''rastuzumab, '''<u>P</u>'''aclitaxel | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Non-pegylated liposomal doxorubicin (Myocet)]] |
− | *[[ | + | *[[Paclitaxel (Taxol)]] |
− | ==== | + | ====Targeted therapy==== |
− | *[[ | + | *[[Trastuzumab (Herceptin)]] |
− | == | + | ==MVC== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | MVC: '''<u>M</u>'''itomycin, '''<u>V</u>'''indesine, '''<u>C</u>'''arboplatin | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Mitomycin (Mutamycin)]] |
− | + | *[[Vindesine (Eldisine)]] | |
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | == | + | ==NIP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | NIP: '''<u>N</u>'''avelbine (Vinorelbine), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin) | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vinorelbine (Navelbine)]] |
− | *[[ | + | *[[Ifosfamide (Ifex)]] |
− | *[[ | + | *[[Cisplatin (Platinol)]] |
− | == | + | ==PD & Pembrolizumab== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PD & Pembrolizumab: '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone, Pembrolizumab | |
===Regimen=== | ===Regimen=== | ||
− | ==== | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | *[[ | + | !style="width: 20%"|Study |
− | *[[ | + | !style="width: 20%"|Years of enrollment |
− | *[[ | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30110-3/fulltext Mateos et al. 2019 (KEYNOTE-183)] | ||
+ | |2016-2017 | ||
+ | |style="background-color:#1a9851"|Phase III (E-esc) | ||
+ | |[[Multiple_myeloma,_relapsed-refractory#Pomalidomide_.26_Dexamethasone_.28PD.29|PD]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior PFS <br>(HR 1.53, 95% CI 1.05-2.22) | ||
+ | |- | ||
+ | |} | ||
+ | ====Targeted therapy==== | ||
+ | *[[Pomalidomide (Pomalyst)]] | ||
+ | ====Chemotherapy==== | ||
+ | *[[Dexamethasone (Decadron)]] | ||
+ | ====Immunotherapy==== | ||
+ | *[[Pembrolizumab (Keytruda)]] | ||
− | == | + | ==PEI== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PEI: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''toposide, '''<u>I</u>'''fosfamide | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] |
− | *[[ | + | *[[Etoposide (Vepesid)]] |
− | + | *[[Ifosfamide (Ifex)]] | |
− | *[[ | ||
− | == | + | ==PELF== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PELF: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>L</u>'''eucovorin, 5-'''<u>F</u>'''U | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] |
− | *[[ | + | *[[Epirubicin (Ellence)]] |
− | *[[ | + | *[[Folinic acid (Leucovorin)]] |
+ | *[[Fluorouracil (5-FU)]] | ||
− | == | + | ==PGT== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PGT: '''<u>P</u>'''latinol (Cisplatin), '''<u>G</u>'''emcitabine, '''<u>T</u>'''axol (Paclitaxel) | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
− | |||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
+ | *[[Gemcitabine (Gemzar)]] | ||
+ | *[[Paclitaxel (Taxol)]] | ||
− | == | + | ==PGV== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PGV: '''<u>P</u>'''latinol (Cisplatin), '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine | |
+ | <br>CGV: '''<u>C</u>'''isplatin, '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine | ||
===Regimen=== | ===Regimen=== | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Cisplatin (Platinol)]] |
− | + | *[[Gemcitabine (Gemzar)]] | |
− | *[[ | + | *[[Vinorelbine (Navelbine)]] |
− | == | + | ==Pemetrexed & Cetuximab== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Pemetrexed (Alimta)]] |
− | + | ====Targeted therapy==== | |
− | *[[ | + | *[[Cetuximab (Erbitux)]] |
− | == | + | ==Pemetrexed & Vandetanib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Pemetrexed (Alimta)]] |
− | + | ====Targeted therapy==== | |
− | + | *[[Vandetanib (Caprelsa)]] | |
− | *[[ | ||
− | == | + | ==Pixantrone & Rituximab== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Pixantrone (Pixuvri)]] |
− | + | ====Targeted therapy==== | |
− | *[[ | + | *[[Rituximab (Rituxan)]] |
− | == | + | ==PVI== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | PVI: '''<u>P</u>'''latinol (Cisplatin), '''<u>V</u>'''indesine, '''<u>I</u>'''fosfamide | |
− | <br> | + | <br>VIP: '''<u>V</u>'''indesine, '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin) |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
− | *[[ | + | *[[Vindesine (Eldisine)]] |
− | *[[ | + | *[[Ifosfamide (Ifex)]] |
+ | |||
+ | ==R-BEACOPP== | ||
+ | R-BEACOPP: '''<u>R</u>'''ituximab, '''<u>B</u>'''leomycin, '''<u>E</u>'''toposide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
+ | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Rituximab (Rituxan)]] | ||
+ | ====Chemotherapy==== | ||
+ | *[[Bleomycin (Blenoxane)]] | ||
+ | *[[Etoposide (Vepesid)]] | ||
+ | *[[Doxorubicin (Adriamycin)]] | ||
+ | *[[Cyclophosphamide (Cytoxan)]] | ||
+ | *[[Vincristine (Oncovin)]] | ||
+ | *[[Procarbazine (Matulane)]] | ||
+ | *[[Prednisone (Sterapred)]] | ||
− | == | + | ==R-MegaCHOEP== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | === | + | R-MegaCHOEP: '''<u>R</u>'''ituximab, high-dose ('''<u>Mega</u>''') '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone |
+ | ====Targeted therapy==== | ||
+ | *[[Rituximab (Rituxan)]] | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Cyclophosphamide (Cytoxan)]] |
− | + | *[[Doxorubicin (Adriamycin)]] | |
− | *[[ | + | *[[Vincristine (Oncovin)]] |
+ | *[[Etoposide (Vepesid)]] | ||
+ | *[[Prednisone (Sterapred)]] | ||
− | == | + | ==Realgar-Indigo naturalis formula monotherapy== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Line 1,323: | Line 1,250: | ||
|} | |} | ||
===Regimen=== | ===Regimen=== | ||
− | |||
− | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Realgar-Indigo naturalis formula]] |
− | == | + | ==TCG== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | TCG: '''<u>T</u>'''axol (Paclitaxel), '''<u>C</u>'''arboplatin, '''<u>G</u>'''emcitabine | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Paclitaxel (Taxol)]] |
− | + | *[[Carboplatin (Paraplatin)]] | |
− | *[[ | + | *[[Gemcitabine (Gemzar)]] |
− | == | + | ==TCHL (Taxotere)== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | TCHL: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>L</u>'''apatinib | ||
===Regimen=== | ===Regimen=== | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] |
+ | *[[Carboplatin (Paraplatin)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Trastuzumab (Herceptin)]] |
+ | *[[Lapatinib (Tykerb)]] | ||
− | == | + | ==TCL (Taxotere)== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TCL: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>L</u>'''apatinib | |
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] |
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | |||
− | |||
− | |||
− | |||
− | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Lapatinib (Tykerb)]] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | == | + | ==TEC== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TEC: '''<u>T</u>'''axol (Paclitaxel), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin | |
− | === | + | ===Regimen=== |
− | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Paclitaxel (Taxol)]] |
− | *[[ | + | *[[Epirubicin (Ellence)]] |
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | |||
− | |||
− | == | + | ==TG+Bev== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | TG+Bev: '''<u>T</u>'''axotere (Docetaxel), '''<u>G</u>'''emcitabine, '''<u>Bev</u>'''acizumab | ||
===Regimen=== | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] | ||
+ | *[[Gemcitabine (Gemzar)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Bevacizumab (Avastin)]] |
− | == | + | ==TH (Taxol) & Everolimus {{#subobject:aa22dd|Regimen=1}}== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TH & Everolimus: '''<u>T</u>'''axol (Paclitaxel), '''<u>H</u>'''erceptin (Trastuzumab), Everolimus | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] |
− | *[[ | + | ====Targeted therapy==== |
− | *[[ | + | *[[Trastuzumab (Herceptin)]] |
+ | *[[Everolimus (Afinitor)]] | ||
− | == | + | ==TL (Taxotere)== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TL: '''<u>T</u>'''axotere (Docetaxel) & '''<u>L</u>'''apatinib | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Docetaxel (Taxotere)]] | *[[Docetaxel (Taxotere)]] | ||
− | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | |||
*[[Lapatinib (Tykerb)]] | *[[Lapatinib (Tykerb)]] | ||
− | == | + | ==TPCV== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TPCV: '''<u>T</u>'''hioguanine, '''<u>P</u>'''rocarbazine, '''<u>C</u>'''CNU, '''<u>V</u>'''incristine | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Thioguanine (Tabloid)]] |
− | *[[ | + | *[[Procarbazine (Matulane)]] |
− | + | *[[Lomustine (CCNU)]] | |
− | *[[ | + | *[[Vincristine (Oncovin)]] |
− | == | + | ==TX+Bev== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TX+Bev: '''<u>T</u>'''axotere (Docetaxel), '''<u>X</u>'''eloda (Capecitabine), '''<u>Bev</u>'''acizumab | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Docetaxel (Taxotere)]] |
− | *[[ | + | *[[Capecitabine (Xeloda)]] |
− | *[[ | + | ====Targeted therapy==== |
+ | *[[Bevacizumab (Avastin)]] | ||
− | == | + | ==VADx== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VADx: '''<u>V</u>'''incristine, '''<u>A</u>'''ra-C (Cytarabine), '''<u>D</u>'''e'''<u>x</u>'''amethasone | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vincristine (Oncovin)]] |
− | *[[ | + | *[[Cytarabine (Ara-C)]] |
− | + | *[[Dexamethasone (Decadron)]] | |
− | *[[ | ||
− | == | + | ==VAPEC-B== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VAPEC-B: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisolone, '''<u>E</u>'''toposide, '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''leomycin | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vincristine (Oncovin)]] |
− | + | *[[Doxorubicin (Adriamycin)]] | |
− | *[[ | + | *[[Prednisolone (Millipred)]] |
− | *[[ | + | *[[Etoposide (Vepesid)]] |
+ | *[[Cyclophosphamide (Cytoxan)]] | ||
+ | *[[Bleomycin (Blenoxane)]] | ||
− | == | + | ==VBM (Vinblastine)== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VBM: '''<u>V</u>'''inblastine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vinblastine (Velban)]] |
− | + | *[[Bleomycin (Blenoxane)]] | |
− | *[[ | + | *[[Methotrexate (MTX)]] |
− | == | + | ==VCE== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VCE: '''<u>V</u>'''incristine, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
− | |||
− | |||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
+ | *[[Carboplatin (Paraplatin)]] | ||
+ | *[[Etoposide (Vepesid)]] | ||
− | == | + | ==Vinorelbine & Hydrocortisone== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vinorelbine (Navelbine)]] |
− | + | ====Endocrine therapy==== | |
− | ==== | + | *[[Hydrocortisone (Cortef)]] |
− | *[[ | ||
− | == | + | ==VNC== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VNC: '''<u>V</u>'''incristine, '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>C</u>'''yclophosphamide | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
− | *[[ | + | *[[Mitoxantrone (Novantrone)]] |
− | *[[ | + | *[[Cyclophosphamide (Cytoxan)]] |
− | == | + | ==VPV== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VPV: '''<u>V</u>'''inblastine, '''<u>P</u>'''latinol (Cisplatin), '''<u>V</u>'''P-16 (Etoposide) | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Vinblastine (Velban)]] |
− | *[[ | + | *[[Cisplatin (Platinol)]] |
− | |||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
− | |||
− | |||
− | == | + | ==VTDC== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | VTDC: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide | |
===Regimen=== | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Bortezomib (Velcade)]] | ||
+ | *[[Thalidomide (Thalomid)]] | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Dexamethasone (Decadron)]] |
− | *[[ | + | *[[Cyclophosphamide (Cytoxan)]] |
− | |||
− | == | + | =Regimens that contain experimental (unapproved) drugs= |
+ | ==Amonafide & Cytarabine== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Amonafide (Quinamed)]] |
− | *[[ | + | *[[Cytarabine (Ara-C)]] |
− | |||
− | == | + | ==Carboplatin & Paclitaxel (CP) & Cediranib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
+ | CP & Cediranib: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Cediranib | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | ==== | + | *[[Paclitaxel (Taxol)]] |
− | *[[ | + | ====Targeted therapy==== |
+ | *[[Cediranib (Recentin)]] | ||
− | == | + | ==Carboplatin & Paclitaxel (CP) & Trebananib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | TC & Trebananib: '''<u>T</u>'''axol (Paclitaxel), '''<u>C</u>'''arboplatin, Trebananib | |
===Regimen=== | ===Regimen=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30178-0/fulltext Vergote et al. 2019 (TRINOVA-3)] | ||
+ | |2012-2014 | ||
+ | |style="background-color:#1a9851"|Phase III (E-esc) | ||
+ | |[[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29_3|TC]] | ||
+ | |style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.93, 95% CI 0.79-1.09) | ||
+ | |- | ||
+ | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Paclitaxel (Taxol)]] |
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | *[[ | + | ====Targeted therapy==== |
+ | *[[Trebananib (AMG 386)]] | ||
− | == | + | ==Carboplatin & Paclitaxel (CP) & Veliparib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | + | CP & Veliparib: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Veliparib | |
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[ | + | *[[Carboplatin (Paraplatin)]] |
− | *[[ | + | *[[Paclitaxel (Taxol)]] |
− | *[[ | + | ====Targeted therapy==== |
+ | *[[Veliparib (ABT-888)]] | ||
+ | |||
+ | ==Docetaxel & Bavituximab== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] | ||
+ | ====Immunotherapy==== | ||
+ | *[[Bavituximab (PGN401)]] | ||
− | == | + | ==Docetaxel & Ganetespib== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen=== | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[ | + | *[[Ganetespib (STA-9090)]] |
− | *[[ | + | |
− | ====Chemotherapy==== | + | ==Erlotinib & Figitumumab== |
− | *[[ | + | {| class="wikitable" style="float:right; margin-left: 5px;" |
− | *[[ | + | |- |
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Erlotinib (Tarceva)]] | ||
+ | *[[Figitumumab (CP-751,871)]] | ||
+ | |||
+ | ==Erlotinib & Onartuzumab== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Erlotinib (Tarceva)]] | ||
+ | *[[Onartuzumab (MetMAb)]] | ||
+ | |||
+ | ==Erlotinib & Tivantinib== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Erlotinib (Tarceva)]] | ||
+ | *[[Tivantinib (ARQ 197)]] | ||
+ | |||
+ | ==Cisplatin & Gemcitabine (GC) & Veliparib== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | GC & Veliparib: '''<u>G</u>'''emcitabine, '''<u>C</u>'''isplatin, Veliparib | ||
+ | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Gemcitabine (Gemzar)]] | ||
+ | *[[Cisplatin (Platinol)]] | ||
+ | ====Targeted therapy==== | ||
+ | *[[Veliparib (ABT-888)]] | ||
+ | |||
+ | ==Ibrutinib & Ublituximab== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | ====Targeted therapy==== | ||
+ | *[[Ibrutinib (Imbruvica)]] | ||
+ | *[[Ublituximab (TG-1101)]] | ||
+ | |||
+ | ==PLD & Trebananib== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ejcancer.com/article/S0959-8049(16)32425-X/fulltext Marth et al. 2016 (TRINOVA-2)] | ||
+ | |2011-2013 | ||
+ | |style="background-color:#1a9851"|Phase III (E-esc) | ||
+ | |[[Ovarian_cancer#Doxorubicin_pegylated_liposomal_monotherapy|PLD]] | ||
+ | |style="background-color:#ffffbf"|Did not meet primary endpoint of PFS <br>(HR 0.92, 95% CI 0.68-1.24) | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Pegylated liposomal doxorubicin (Doxil)]] | ||
+ | ====Targeted therapy==== | ||
+ | *[[Trebananib (AMG 386)]] |
Revision as of 02:00, 16 July 2021
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the HemOnc Ontology and for historic interest.
Regimens composed solely of approved drugs
3M
back to top |
3M: Mitomycin, Mitoxantrone, Methotrexate
Regimen
Chemotherapy
5-FU & RT
back to top |
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
7+3i & Clofarabine
back to top |
7+3i & Clofarabine: 7 days of cytarabine, 3 days of idarubicin, Clofarabine
Regimen
Chemotherapy
7+3i & Lenalidomide
back to top |
7+3i & Lenalidomide: 7 days of cytarabine, 3 days of idarubicin, Lenalidomide
Regimen
Chemotherapy
Targeted therapy
7+4i
back to top |
7+4i: 7 days of cytarabine, 4 days of idarubicin
Regimen
Chemotherapy
7+5d
back to top |
7+5d: 7 days of cytarabine, 5 days of daunorubicin
Regimen
Chemotherapy
Abiraterone & Enzalutamide
back to top |
Regimen
Endocrine therapy
ACP
back to top |
ACP: Atezolizumab, Carboplatin, Paclitaxel
Regimen
Immunotherapy
Chemotherapy
Afatinib & Vinorelbine
back to top |
Regimen
Chemotherapy
Targeted therapy
A-ICE
back to top |
A-ICE: ATRA, Idarubicin, Cytarabine, Etoposide
Regimen
Targeted therapy
Chemotherapy
AME
back to top |
AME: Ara-C (Cytarabine), Mitoxantrone, Etoposide
Regimen
Chemotherapy
Amsacrine & IDAC
back to top |
Amsacrine & IDAC: Amsacrine & Intermediate Dose Ara-C (Cytarabine)
Regimen
Chemotherapy
ATRA, Cytarabine, Etoposide
back to top |
Regimen
Targeted therapy
Chemotherapy
Bortezomib & Bevacizumab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
White et al. 2012 (AMBER) | 2007-2009 | Randomized Phase II (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.74, 95% CI 0.43-1.28) |
Targeted therapy
Bortezomib & Siltuximab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Orlowski et al. 2015 (CR012784) | 2006-2009 | Randomized Phase II (E-esc) | Bortezomib | Did not meet primary endpoint of PFS (HR 0.87, 95% CI 0.65-1.16) |
Targeted therapy
BTH (Taxotere)
back to top |
BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)
Regimen
Chemotherapy
Targeted therapy
BTOC
back to top |
BTOC: BCNU, Thiotepa, Oncovin (Vincristine), Cyclophosphamide
Regimen
Chemotherapy
CAD
back to top |
CAD: Cyclophosphamide, Adriamycin (Doxorubicin), DDP (Cisplatin)
Regimen
Chemotherapy
Capecitabine & Cisplatin (CX) & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Cisplatin (CX) & Ramucirumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Ruxolitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sorafenib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Sunitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Capecitabine & Vinflunine
back to top |
Regimen
Chemotherapy
Capecitabine & Vinorelbine
back to top |
NX: Navelbine (Vinorelbine) & Xeloda (Capecitabine)
Regimen
Chemotherapy
Capecitabine, Cisplatin, Cetuximab, RT
back to top |
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
- Concurrent radiation therapy
Capecitabine, Erlotinib, RT
back to top |
Regimen
Chemotherapy
Targeted therapy
Radiotherapy
- Concurrent radiation therapy
CarboMIP
back to top |
CarboMIP: Carboplatin, Mitomycin, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
Carboplatin & Epirubicin
back to top |
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Bexarotene
back to top |
CP & Bexarotene: Carboplatin, Paclitaxel, Bexarotene
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Cetuximab
back to top |
CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Erlotinib
back to top |
CP & Erlotinib: Carboplatin, Paclitaxel, Erlotinib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & PLD
back to top |
TC & PLD: Taxol (Paclitaxel), Carboplatin, Pegylated Liposomal Doxorubicin
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Sorafenib
back to top |
CP & Sorafenib: Carboplatin, Paclitaxel, Sorafenib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Topotecan
back to top |
TC & Topotecan: Taxol (Paclitaxel), Carboplatin, Topotecan
Regimen
Chemotherapy
Carboplatin & Topotecan
back to top |
Regimen
Chemotherapy
CBM
back to top |
CBM: Capecitabine, Bevacizumab, Mitomycin
Regimen
Chemotherapy
Targeted therapy
CCG
back to top |
CCG: Cisplatin, Carboplatin, Gemcitabine
Regimen
Chemotherapy
Carboplatin & Etoposide (CE) & Ipilimumab
back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
Carboplatin & Etoposide (CE) & Thalidomide
back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
CIB
back to top |
CIB: Cisplatin, Ifosfamide, Bleomycin
Regimen
Chemotherapy
Cisplatin & Methotrexate
back to top |
Regimen
Chemotherapy
Cisplatin & Treosulfan
back to top |
Regimen
Chemotherapy
Cisplatin & Vincristine
back to top |
Regimen
Chemotherapy
Cisplatin, Avelumab, RT
back to top |
Regimen
Chemotherapy
Immunotherapy
Radiotherapy
- Concurrent radiation therapy
Cisplatin, Pemetrexed, RT
back to top |
Regimen
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
CODE
back to top |
CODE: Cisplatin, Oncovin (Vincristine), Doxorubicin, Etoposide
Regimen
Chemotherapy
CYVADIC
back to top |
CYVADIC: CYclophosphamide, Vincristine, ADriamycin (Doxorubicin), Imidazole Carboxamide (Dacarbazine)
Regimen
Chemotherapy
DBCT
back to top |
DBCT: Dacarbazine, BCNU (Carmustine), Cisplatin, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Docetaxel & Gefitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Lapatinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Pertuzumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Selumetinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Sunitinib
back to top |
Regimen
Chemotherapy
Targeted therapy
Docetaxel & ziv-Aflibercept
back to top |
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Etoposide
back to top |
Regimen
Chemotherapy
Doxorubicin & Paclitaxel
back to top |
Regimen
Chemotherapy
Doxorubicin & Sorafenib
back to top |
Regimen
Chemotherapy
Targeted therapy
Doxorubicin & Streptozocin
back to top |
Regimen
Chemotherapy
Doxorubicin & Vinorelbine
back to top |
Regimen
Chemotherapy
EAP
back to top |
EAP: Etoposide, Adriamycin (Doxorubicin), Platinol (Cisplatin)
Regimen
Chemotherapy
ECVBP
back to top |
ECVBP: Epirubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
Regimen
Chemotherapy
- Epirubicin (Ellence)
- Cyclophosphamide (Cytoxan)
- Vindesine (Eldisine)
- Bleomycin (Blenoxane)
- Prednisone (Sterapred)
ELF
back to top |
ELF: Etoposide, Leucovorin, 5-FU
Regimen
Chemotherapy
Encorafenib monotherapy
back to top |
Regimen
Targeted therapy
EP & Ipilimumab
back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
back to top |
EP, Tamoxifen, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Endocrine therapy
Radiotherapy
- Concurrent thoracic radiation therapy
Erlotinib & Sunitinib
back to top |
Regimen
Targeted therapy
Everolimus & Vinorelbine
back to top |
Regimen
Chemotherapy
Targeted therapy
E-GEMOX
back to top |
E-GEMOX: Erlotinib, GEMcitabine, OXaliplatin
Regimen
Targeted therapy
Chemotherapy
FAP
back to top |
FAP: Fluorouracil, Alfa interferon, Platinol (Cisplatin)
Regimen
Chemotherapy
Immunotherapy
FEC & HP
back to top |
FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab
Regimen
Chemotherapy
Targeted therapy
FLA
back to top |
FLA: FLudarabine & Ara-C (Cytarabine)
Regimen
Chemotherapy
FLAG-Ida & GO
back to top |
FLAG-Ida & GO: FLudarabine, Ara-C (Cytarabine), G-CSF (Lenograstim), Idarubicin, Gemtuzumab Ozogamicin
Regimen
Chemotherapy
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days 2 to 6
- Cytarabine (Ara-C) 2000 mg/m2 IV over 4 hours once per day on days 2 to 6, given 4 hours after fludarabine
- Idarubicin (Idamycin) 8 mg/m2 IV once per day on days 4 to 6
Growth factor therapy
Targeted therapy
FLAI
back to top |
FLAI: FLudarabine, Ara-C (Cytarabine), Idarubicin
FIA: Fludarabine, Idarubicin, Ara-C (Cytarabine)
Regimen
Chemotherapy
FOLF-CB
back to top |
FOLF-CB: FOLinic acid, Fluorouracil, Cetuximab, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
FULV & Trimetrexate
back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
GVP
back to top |
GVP: Gemcitabine, Vinorelbine, Platinol (Cisplatin)
Regimen
Chemotherapy
ICE, ATRA, GO
back to top |
ICE, ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid, Gemtuzumab Ozogamicin
Regimen
Chemotherapy
Targeted therapy
Ixabepilone & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
ME
back to top |
ME: Mitoxantrone & Etoposide
Regimen
Chemotherapy
MEV
back to top |
MEV: Mitomycin, Etoposide, Vindesine
Regimen
Chemotherapy
MFL
back to top |
MFL: Methyl-lomustine (MeCCNU), 5-FU, Leucovorin (Folinic acid)
Regimen
Chemotherapy
MFT
back to top |
MFL: Methotrexate, 5-FU, Tamoxifen
Regimen
Chemotherapy
Endocrine therapy
Mitoxantrone & Hydrocortisone
back to top |
Regimen
Chemotherapy
Endocrine therapy
MMF
back to top |
MMF: Methyl-lomustine (MeCCNU), Mitomycin, 5-FU
Regimen
Chemotherapy
MPP
back to top |
MPP: Melphalan, Prednisone, Procarbazine
Regimen
Chemotherapy
MTP
back to top |
MTP: Myocet (Non-pegylated liposomal doxorubicin), Trastuzumab, Paclitaxel
Regimen
Chemotherapy
Targeted therapy
MVC
back to top |
MVC: Mitomycin, Vindesine, Carboplatin
Regimen
Chemotherapy
NIP
back to top |
NIP: Navelbine (Vinorelbine), Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
PD & Pembrolizumab
back to top |
PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Mateos et al. 2019 (KEYNOTE-183) | 2016-2017 | Phase III (E-esc) | PD | Seems to have inferior PFS (HR 1.53, 95% CI 1.05-2.22) |
Targeted therapy
Chemotherapy
Immunotherapy
PEI
back to top |
PEI: Platinol (Cisplatin), Etoposide, Ifosfamide
Regimen
Chemotherapy
PELF
back to top |
PELF: Platinol (Cisplatin), Epirubicin, Leucovorin, 5-FU
Regimen
Chemotherapy
PGT
back to top |
PGT: Platinol (Cisplatin), Gemcitabine, Taxol (Paclitaxel)
Regimen
Chemotherapy
PGV
back to top |
PGV: Platinol (Cisplatin), Gemcitabine, Vinorelbine
CGV: Cisplatin, Gemcitabine, Vinorelbine
Regimen
Chemotherapy
Pemetrexed & Cetuximab
back to top |
Regimen
Chemotherapy
Targeted therapy
Pemetrexed & Vandetanib
back to top |
Regimen
Chemotherapy
Targeted therapy
Pixantrone & Rituximab
back to top |
Regimen
Chemotherapy
Targeted therapy
PVI
back to top |
PVI: Platinol (Cisplatin), Vindesine, Ifosfamide
VIP: Vindesine, Ifosfamide, Platinol (Cisplatin)
Regimen
Chemotherapy
R-BEACOPP
R-BEACOPP: Rituximab, Bleomycin, Etoposide, Adriamycin (Doxorubicin), Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Targeted therapy
Chemotherapy
- Bleomycin (Blenoxane)
- Etoposide (Vepesid)
- Doxorubicin (Adriamycin)
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
- Prednisone (Sterapred)
R-MegaCHOEP
back to top |
R-MegaCHOEP: Rituximab, high-dose (Mega) Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone
Targeted therapy
Chemotherapy
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Vincristine (Oncovin)
- Etoposide (Vepesid)
- Prednisone (Sterapred)
Realgar-Indigo naturalis formula monotherapy
back to top |
Regimen
Targeted therapy
TCG
back to top |
TCG: Taxol (Paclitaxel), Carboplatin, Gemcitabine
Regimen
Chemotherapy
TCHL (Taxotere)
back to top |
TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib
Regimen
Chemotherapy
Targeted therapy
TCL (Taxotere)
back to top |
TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib
Regimen
Chemotherapy
Targeted therapy
TEC
back to top |
TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin
Regimen
Chemotherapy
TG+Bev
back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TH (Taxol) & Everolimus
back to top |
TH & Everolimus: Taxol (Paclitaxel), Herceptin (Trastuzumab), Everolimus
Regimen
Chemotherapy
Targeted therapy
TL (Taxotere)
back to top |
TL: Taxotere (Docetaxel) & Lapatinib
Regimen
Chemotherapy
Targeted therapy
TPCV
back to top |
TPCV: Thioguanine, Procarbazine, CCNU, Vincristine
Regimen
Chemotherapy
TX+Bev
back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab
Regimen
Chemotherapy
Targeted therapy
VADx
back to top |
VADx: Vincristine, Ara-C (Cytarabine), Dexamethasone
Regimen
Chemotherapy
VAPEC-B
back to top |
VAPEC-B: Vincristine, Adriamycin (Doxorubicin), Prednisolone, Etoposide, Cyclophosphamide, Bleomycin
Regimen
Chemotherapy
- Vincristine (Oncovin)
- Doxorubicin (Adriamycin)
- Prednisolone (Millipred)
- Etoposide (Vepesid)
- Cyclophosphamide (Cytoxan)
- Bleomycin (Blenoxane)
VBM (Vinblastine)
back to top |
VBM: Vinblastine, Bleomycin, Methotrexate
Regimen
Chemotherapy
VCE
back to top |
VCE: Vincristine, Carboplatin, Etoposide
Regimen
Chemotherapy
Vinorelbine & Hydrocortisone
back to top |
Regimen
Chemotherapy
Endocrine therapy
VNC
back to top |
VNC: Vincristine, Novantrone (Mitoxantrone), Cyclophosphamide
Regimen
Chemotherapy
VPV
back to top |
VPV: Vinblastine, Platinol (Cisplatin), VP-16 (Etoposide)
Regimen
Chemotherapy
VTDC
back to top |
VTDC: Velcade (Bortezomib), Thalidomide, Dexamethasone, Cyclophosphamide
Regimen
Targeted therapy
Chemotherapy
Regimens that contain experimental (unapproved) drugs
Amonafide & Cytarabine
back to top |
Regimen
Chemotherapy
Carboplatin & Paclitaxel (CP) & Cediranib
back to top |
CP & Cediranib: Carboplatin, Paclitaxel, Cediranib
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Trebananib
back to top |
TC & Trebananib: Taxol (Paclitaxel), Carboplatin, Trebananib
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Vergote et al. 2019 (TRINOVA-3) | 2012-2014 | Phase III (E-esc) | TC | Did not meet primary endpoint of PFS (HR 0.93, 95% CI 0.79-1.09) |
Chemotherapy
Targeted therapy
Carboplatin & Paclitaxel (CP) & Veliparib
back to top |
CP & Veliparib: Carboplatin, Paclitaxel, Veliparib
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Bavituximab
back to top |
Regimen
Chemotherapy
Immunotherapy
Docetaxel & Ganetespib
back to top |
Regimen
Chemotherapy
Targeted therapy
Erlotinib & Figitumumab
back to top |
Regimen
Targeted therapy
Erlotinib & Onartuzumab
back to top |
Regimen
Targeted therapy
Erlotinib & Tivantinib
back to top |
Regimen
Targeted therapy
Cisplatin & Gemcitabine (GC) & Veliparib
back to top |
GC & Veliparib: Gemcitabine, Cisplatin, Veliparib
Regimen
Chemotherapy
Targeted therapy
Ibrutinib & Ublituximab
back to top |
Regimen
Targeted therapy
PLD & Trebananib
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Marth et al. 2016 (TRINOVA-2) | 2011-2013 | Phase III (E-esc) | PLD | Did not meet primary endpoint of PFS (HR 0.92, 95% CI 0.68-1.24) |